Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence
En palabras de los autores
The absence of accurate, noninvasive, scalable screening tools keeps early esophageal cancer (EC) detection a global health challenge. Although noncontrast computed tomography (NC CT) is widely accessible, the esophagus is a hollow tubular structure prone to collapse and motion artifacts, making small early malignant lesions difficult to distinguish from normal tissue. Here we developed the Esophageal AI-Guided malignant Lesion Evaluation (EAGLE) model to detect precancerous lesions and cancer from chest NC CT, a task historically considered impossible. EAGLE was trained on 6,813 patients from two centers and validated across 12 centers in three countries involving 80,612 patients in opportunistic and population-based screening settings. For opportunistic screening on existing CT scans, multicenter external test cohorts (eight centers, n = 11,466) achieved 98.5% specificity, with 90.0% sensitivity for cancer and 52.5% for precancerous lesions; low-dose CT (LDCT) validation (two centers, n = 1,607) showed comparable performance, supporting EC screening through lung-cancer screening programs. Calibration in a real-world cohort (three centers, n = 35,402) reduced false positives by 72.7% while preserving sensitivity; prospective hospital validation (n = 17,446) achieved a 42.2% PPV, and real-world low-dose screening (n = 10,959) reached 99.94% specificity. EAGLE also detected precancerous lesions-in paired CT-endoscopy cohorts (two centers, n = 702), sensitivities were 65.0% for precancerous lesions and 78.4% for stage I EC at a higher-sensitivity operating point. Exploratory analyses of a prospectively enrolled cohort suggest that referring high-risk individuals for endoscopy could improve screening efficiency. In conclusion, EAGLE has the potential to serve as a scalable tool for early EC screening. Chictr.org.cn identifier: ChiCTR2300074806 .
En palabras simples Resumen con IA
Para la detección de cáncer en tomografías existentes, el modelo logró 90.0% de sensibilidad y 98.5% de especificidad. En cribado de dosis baja en el mundo real, alcanzó 99.94% de especificidad, y la calibración redujo los falsos positivos en 72.7%. Los autores concluyen que EAGLE tiene el potencial de servir como una herramienta escalable para el cribado temprano del cáncer de esófago.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale. Se eliminaron 2 oraciones por no estar respaldadas por el abstract.
Apareció: jueves, 24 de septiembre. Nature Medicine. Revista con revisión por pares.